The novel use of combined IL-1 and IL-6 inhibition in a patient with severe, aggressive, erosive, systemic-onset juvenile idiopathic arthritis
Freeman Hospital, Newcastle-Upon- Tyne Hospitals NHS Foundation Trust, Newcastle-Upon-Tyne
Eur J Rheumatol 2017; 4: 68-69
This article was viewed 171 times, downloaded 80 times
Key Words: Juvenile Idiopathic Arthritis, biologic therapy, systemic-onset
Systemic-onset juvenile idiopathic arthritis (SoJIA) is a form of juvenile idiopathic arthritis (JIA) that typically presents with prominent systemic features and accounts for approximately 10–15% of children with JIA. Pro-inflammatory cytokine pathways are thought to be involved in its pathogenesis, including interleukin-1 (IL-1) and interleukin-6 (IL-6), and laboratory tests demonstrate a prominent inflammatory response with high CRP and ferritin levels. We present a case of severe, aggressive, erosive SoJIA in a 17-year-old male resistant to multiple biologic therapies treated with a novel combination of IL-1 and IL-6 blockade along with subcutaneous methotrexate.